1. known hypersensitivity/allergy to lopinavir or ritonavir. 2. current use of lpv/r for the treatment or prevention of hiv infection. 3. receipt of lpv/r in the context of this trial or any other trial of covid-19 pep within 2 days or less prior to the last known contact with the index covid-19 case. the two day time window is intended to ensure that exposure would not have occurred in the presence of clinically relevant drug levels (five times the elimination half-life of lpv/r, which is estimated at 4-6 hours with prolonged use). 4. baseline respiratory tract specimen positive for covid-19. randomized participants whose baseline samples subsequently show covid-19 will have study drug discontinued but still remain under observation. 5. current breastfeeding, due to potential for serious adverse reactions in nursing infants exposed to lpv/r 6. concomitant medications with prohibited drug interactions with lpv/r that cannot be temporarily suspended/replaced, including but not restricted to: 37 * alfuzosin (e.g. xatral®) * amiodarone (e.g. cordarone™) * apalutamide (e.g. erleada™) * astemizole\*, terfenadine\* * cisapride\* * colchicine, when used in patients with renal and/or hepatic impairment * dronedarone (e.g., multaq®) * elbasvir/grazoprevir (e.g., zepatiertm) * ergotamine\* (e.g. cafergot®\*), dihydroergotamine (e.g. migranal®), ergonovine, methylergonovine\* * fusidic acid (e.g., fucidin®), systemic\* * lurasidone (e.g., latuda®), pimozide (e.g., orap®\*) * neratinib (e.g., nerlynx®) * sildenafil (e.g., revatio®) * triazolam (e.g. halcion®), midazolam oral\* * rifampin (e.g. rimactane®\*, rifadin®, rifater®\*, rifamate®\*) * st. john's wort * tadalafil (e.g. adcirca®) * venetoclax (e.g. venclexta®) * lovastatin (e.g., mevacor®\*), lomitapide (e.g., juxtapidtm) or simvastatin (e.g., zocor®) * vardenafil (e.g., levitra® or staxyn®) * salmeterol (e.g., advair® or serevent®) * denotes products not marketed in canada

1. known hypersensitivity/allergy to lopinavir or ritonavir. 2. current use of lpv/r for the treatment or prevention of hiv infection. 3. receipt of lpv/r in the context of this trial or any other trial of covid-19 pep within 2 days or less prior to the last known contact with the index covid-19 case. the two day time window is intended to ensure that exposure would not have occurred in the presence of clinically relevant drug levels (five times the elimination half-life of lpv/r, which is estimated at 4-6 hours with prolonged use). 4. baseline respiratory tract specimen positive for covid-19. randomized participants whose baseline samples subsequently show covid-19 will have study drug discontinued but still remain under observation. 5. current breastfeeding, due to potential for serious adverse reactions in nursing infants exposed to lpv/r 6. concomitant medications with prohibited drug interactions with lpv/r that cannot be temporarily suspended/replaced, including but not restricted to: 37 * alfuzosin (e.g. xatral®) * amiodarone (e.g. cordarone™) * apalutamide (e.g. erleada™) * astemizole\*, terfenadine\* * cisapride\* * colchicine, when used in patients with renal and/or hepatic impairment * dronedarone (e.g., multaq®) * elbasvir/grazoprevir (e.g., zepatiertm) * ergotamine\* (e.g. cafergot®\*), dihydroergotamine (e.g. migranal®), ergonovine, methylergonovine\* * fusidic acid (e.g., fucidin®), systemic\* * lurasidone (e.g., latuda®), pimozide (e.g., orap®\*) * neratinib (e.g., nerlynx®) * sildenafil (e.g., revatio®) * triazolam (e.g. halcion®), midazolam oral\* * rifampin (e.g. rimactane®\*, rifadin®, rifater®\*, rifamate®\*) * st. john's wort * tadalafil (e.g. adcirca®) * venetoclax (e.g. venclexta®) * lovastatin (e.g., mevacor®\*), lomitapide (e.g., juxtapidtm) or simvastatin (e.g., zocor®) * vardenafil (e.g., levitra® or staxyn®) * salmeterol (e.g., advair® or serevent®) * denotes products not marketed in canada

known hypersensitivity/allergy to lopinavir or ritonavir. current use of lpv/r for the treatment or prevention of hiv infection. receipt of lpv/r in the context of this trial or any other trial of covid-19 pep within 2 days or less prior to the last known contact with the index covid-19 case. the two day time window is intended to ensure that exposure would not have occurred in the presence of clinically relevant drug levels (five times the elimination half-life of lpv/r, which is estimated at 4-6 hours with prolonged use). baseline respiratory tract specimen positive for covid-19. randomized participants whose baseline samples subsequently show covid-19 will have study drug discontinued but still remain under observation. current breastfeeding, due to potential for serious adverse reactions in nursing infants exposed to lpv/r concomitant medications with prohibited drug interactions with lpv/r that cannot be temporarily suspended/replaced, including but not restricted to: 37 alfuzosin (e.g. xatral®) amiodarone (e.g. cordarone™) apalutamide (e.g. erleada™) astemizole*, terfenadine* cisapride* colchicine, when used in patients with renal and/or hepatic impairment dronedarone (e.g., multaq®) elbasvir/grazoprevir (e.g., zepatiertm) ergotamine* (e.g. cafergot®*), dihydroergotamine (e.g. migranal®), ergonovine, methylergonovine* fusidic acid (e.g., fucidin®), systemic* lurasidone (e.g., latuda®), pimozide (e.g., orap®*) neratinib (e.g., nerlynx®) sildenafil (e.g., revatio®) triazolam (e.g. halcion®), midazolam oral* rifampin (e.g. rimactane®*, rifadin®, rifater®*, rifamate®*) st. john's wort tadalafil (e.g. adcirca®) venetoclax (e.g. venclexta®) lovastatin (e.g., mevacor®*), lomitapide (e.g., juxtapidtm) or simvastatin (e.g., zocor®) vardenafil (e.g., levitra® or staxyn®) salmeterol (e.g., advair® or serevent®) denotes products not marketed in canada

known hypersensitivity/allergy to lopinavir or ritonavir. current use of lpv/r for the treatment or prevention of hiv infection. receipt of lpv/r in the context of this trial or any other trial of covid-19 pep within 2 days or less prior to the last known contact with the index covid-19 case. the two day time window is intended to ensure that exposure would not have occurred in the presence of clinically relevant drug levels (five times the elimination half-life of lpv/r, which is estimated at 4-6 hours with prolonged use). baseline respiratory tract specimen positive for covid-19. randomized participants whose baseline samples subsequently show covid-19 will have study drug discontinued but still remain under observation. current breastfeeding, due to potential for serious adverse reactions in nursing infants exposed to lpv/r concomitant medications with prohibited drug interactions with lpv/r that cannot be temporarily suspended/replaced, including but not restricted to: 37 alfuzosin (e.g. xatral®) amiodarone (e.g. cordarone™) apalutamide (e.g. erleada™) astemizole*, terfenadine* cisapride* colchicine, when used in patients with renal and/or hepatic impairment dronedarone (e.g., multaq®) elbasvir/grazoprevir (e.g., zepatiertm) ergotamine* (e.g. cafergot®*), dihydroergotamine (e.g. migranal®), ergonovine, methylergonovine* fusidic acid (e.g., fucidin®), systemic* lurasidone (e.g., latuda®), pimozide (e.g., orap®*) neratinib (e.g., nerlynx®) sildenafil (e.g., revatio®) triazolam (e.g. halcion®), midazolam oral* rifampin (e.g. rimactane®*, rifadin®, rifater®*, rifamate®*) st. john's wort tadalafil (e.g. adcirca®) venetoclax (e.g. venclexta®) lovastatin (e.g., mevacor®*), lomitapide (e.g., juxtapidtm) or simvastatin (e.g., zocor®) vardenafil (e.g., levitra® or staxyn®) salmeterol (e.g., advair® or serevent®) denotes products not marketed in canada

1. known hypersensitivity/allergy to lopinavir or ritonavir. 2. current use of lpv/r for the treatment or prevention of hiv infection. 3. receipt of lpv/r in the context of this trial or any other trial of covid-19 pep within 2 days or less prior to the last known contact with the index covid-19 case. the two day time window is intended to ensure that exposure would not have occurred in the presence of clinically relevant drug levels (five times the elimination half-life of lpv/r, which is estimated at 4-6 hours with prolonged use). 4. baseline respiratory tract specimen positive for covid-19. randomized participants whose baseline samples subsequently show covid-19 will have study drug discontinued but still remain under observation. 5. current breastfeeding, due to potential for serious adverse reactions in nursing infants exposed to lpv/r 6. concomitant medications with prohibited drug interactions with lpv/r that cannot be temporarily suspended/replaced, including but not restricted to: 37 - alfuzosin (e.g. xatral®) - amiodarone (e.g. cordarone™) - apalutamide (e.g. erleada™) - astemizole*, terfenadine* - cisapride* - colchicine, when used in patients with renal and/or hepatic impairment - dronedarone (e.g., multaq®) - elbasvir/grazoprevir (e.g., zepatiertm) - ergotamine* (e.g. cafergot®*), dihydroergotamine (e.g. migranal®), ergonovine, methylergonovine* - fusidic acid (e.g., fucidin®), systemic* - lurasidone (e.g., latuda®), pimozide (e.g., orap®*) - neratinib (e.g., nerlynx®) - sildenafil (e.g., revatio®) - triazolam (e.g. halcion®), midazolam oral* - rifampin (e.g. rimactane®*, rifadin®, rifater®*, rifamate®*) - st. john's wort - tadalafil (e.g. adcirca®) - venetoclax (e.g. venclexta®) - lovastatin (e.g., mevacor®*), lomitapide (e.g., juxtapidtm) or simvastatin (e.g., zocor®) - vardenafil (e.g., levitra® or staxyn®) - salmeterol (e.g., advair® or serevent®) - denotes products not marketed in canada

1. known hypersensitivity/allergy to lopinavir or ritonavir. 2. current use of lpv/r for the treatment or prevention of hiv infection. 3. receipt of lpv/r in the context of this trial or any other trial of covid-19 pep within 2 days or less prior to the last known contact with the index covid-19 case. the two day time window is intended to ensure that exposure would not have occurred in the presence of clinically relevant drug levels (five times the elimination half-life of lpv/r, which is estimated at 4-6 hours with prolonged use). 4. baseline respiratory tract specimen positive for covid-19. randomized participants whose baseline samples subsequently show covid-19 will have study drug discontinued but still remain under observation. 5. current breastfeeding, due to potential for serious adverse reactions in nursing infants exposed to lpv/r 6. concomitant medications with prohibited drug interactions with lpv/r that cannot be temporarily suspended/replaced, including but not restricted to: 37 - alfuzosin (e.g. xatral®) - amiodarone (e.g. cordarone™) - apalutamide (e.g. erleada™) - astemizole*, terfenadine* - cisapride* - colchicine, when used in patients with renal and/or hepatic impairment - dronedarone (e.g., multaq®) - elbasvir/grazoprevir (e.g., zepatiertm) - ergotamine* (e.g. cafergot®*), dihydroergotamine (e.g. migranal®), ergonovine, methylergonovine* - fusidic acid (e.g., fucidin®), systemic* - lurasidone (e.g., latuda®), pimozide (e.g., orap®*) - neratinib (e.g., nerlynx®) - sildenafil (e.g., revatio®) - triazolam (e.g. halcion®), midazolam oral* - rifampin (e.g. rimactane®*, rifadin®, rifater®*, rifamate®*) - st. john's wort - tadalafil (e.g. adcirca®) - venetoclax (e.g. venclexta®) - lovastatin (e.g., mevacor®*), lomitapide (e.g., juxtapidtm) or simvastatin (e.g., zocor®) - vardenafil (e.g., levitra® or staxyn®) - salmeterol (e.g., advair® or serevent®) - denotes products not marketed in canada